163 related articles for article (PubMed ID: 37767674)
1. Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF: The DELIVER Trial.
Peikert A; Bart BA; Vaduganathan M; Claggett BL; Kulac IJ; Kosiborod MN; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD; Vardeny O
JACC Heart Fail; 2024 Apr; 12(4):631-644. PubMed ID: 37767674
[TBL] [Abstract][Full Text] [Related]
2. Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction.
Cunningham JW; Vaduganathan M; Claggett BL; Kulac IJ; Desai AS; Jhund PS; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; McGrath MM; O'Meara E; Wilderäng U; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2022 Oct; 80(14):1302-1310. PubMed ID: 36041912
[TBL] [Abstract][Full Text] [Related]
3. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR; Claggett BL; Vaduganathan M; Desai A; Jhund P; Vardeny O; Fang JC; de Boer RA; Docherty KF; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
JAMA Cardiol; 2024 Feb; 9(2):144-152. PubMed ID: 37952176
[TBL] [Abstract][Full Text] [Related]
4. Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Myhre PL; Vaduganathan M; Claggett BL; Miao ZM; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JACC Heart Fail; 2022 Dec; 10(12):902-913. PubMed ID: 36114137
[TBL] [Abstract][Full Text] [Related]
5. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
Kosiborod MN; Bhatt AS; Claggett BL; Vaduganathan M; Kulac IJ; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Vardeny O; Lindholm D; Wilderäng U; Bengtsson O; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2023 Feb; 81(5):460-473. PubMed ID: 36526515
[TBL] [Abstract][Full Text] [Related]
6. Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Vaduganathan M; Claggett BL; Jhund P; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Hegde SM; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JAMA Cardiol; 2022 Dec; 7(12):1259-1263. PubMed ID: 36190011
[TBL] [Abstract][Full Text] [Related]
7. Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Polypharmacy Status.
Peikert A; Goyal P; Vaduganathan M; Claggett BL; Kulac IJ; Miao ZM; Vardeny O; Kosiborod MN; Desai AS; Jhund PS; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JACC Heart Fail; 2023 Oct; 11(10):1380-1393. PubMed ID: 37294244
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER.
Peikert A; Vaduganathan M; Claggett BL; Kulac IJ; Foà A; Desai AS; Jhund PS; Carberry J; Lam CSP; Kosiborod MN; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Køber L; Ponikowski P; Sabatine MS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Eur J Heart Fail; 2024 Apr; 26(4):912-924. PubMed ID: 38487939
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880
[TBL] [Abstract][Full Text] [Related]
10. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: a post-hoc analysis of the ATHENA trial.
Vaduganathan M; Piccini JP; Camm AJ; Crijns HJGM; Anker SD; Butler J; Stewart J; Braceras R; Albuquerque APA; Wieloch M; Hohnloser SH
Eur J Heart Fail; 2022 Jun; 24(6):1094-1101. PubMed ID: 35293087
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Safety of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction According to Age: The DELIVER Trial.
Peikert A; Martinez FA; Vaduganathan M; Claggett BL; Kulac IJ; Desai AS; Jhund PS; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Shah SJ; Katova T; Merkely B; Vardeny O; Wilderäng U; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Circ Heart Fail; 2022 Oct; 15(10):e010080. PubMed ID: 36029467
[TBL] [Abstract][Full Text] [Related]
12. Heart failure, chronic obstructive pulmonary disease and efficacy and safety of dapagliflozin in heart failure with mildly reduced or preserved ejection fraction: Insights from DELIVER.
Butt JH; Lu H; Kondo T; Bachus E; de Boer RA; Inzucchi SE; Jhund PS; Kosiborod MN; Lam CSP; Martinez FA; Vaduganathan M; Solomon SD; McMurray JJV
Eur J Heart Fail; 2023 Nov; 25(11):2078-2090. PubMed ID: 37634087
[TBL] [Abstract][Full Text] [Related]
13. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR; Claggett BL; Vaduganathan M; Desai AS; Jhund P; de Boer RA; Docherty K; Fang J; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
JAMA Cardiol; 2023 Jan; 8(1):56-65. PubMed ID: 36326604
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum.
Butt JH; Docherty KF; Claggett BL; Desai AS; Fang JC; Petersson M; Langkilde AM; de Boer RA; Cabrera Honorio JW; Hernandez AF; Inzucchi SE; Kosiborod MN; Køber L; Lam CSP; Martinez FA; Ponikowski P; Sabatine MS; Vardeny O; O'Meara E; Saraiva JFK; Shah SJ; Vaduganathan M; Jhund PS; Solomon SD; McMurray JJV
JACC Heart Fail; 2023 Apr; 11(4):375-388. PubMed ID: 36881399
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.
Inzucchi SE; Claggett BL; Vaduganathan M; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Verma S; Han Y; Kerr Saraiva JF; Bengtsson O; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Lancet Diabetes Endocrinol; 2022 Dec; 10(12):869-881. PubMed ID: 36372069
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial.
Chatur S; Vaduganathan M; Claggett B; Vardeny O; Desai AS; Jhund PS; de Boer RA; Lam CSP; Kosiborod MN; Shah SJ; Martinez F; Inzucchi SE; Hernandez AF; Haddad T; Mitter SS; Miao ZM; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
Eur Heart J; 2023 Aug; 44(31):2930-2943. PubMed ID: 37220093
[TBL] [Abstract][Full Text] [Related]
18. Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction.
Berg DD; Jhund PS; Docherty KF; Murphy SA; Verma S; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Bengtsson O; Ponikowski P; Sjöstrand M; Solomon SD; McMurray JJV; Sabatine MS
JAMA Cardiol; 2021 May; 6(5):499-507. PubMed ID: 33595593
[TBL] [Abstract][Full Text] [Related]
19. Effect of Dapagliflozin on Total Heart Failure Events in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Analysis of the DELIVER Trial.
Jhund PS; Claggett BL; Talebi A; Butt JH; Gasparyan SB; Wei LJ; McCaw ZR; Wilderäng U; Bengtsson O; Desai AS; Petersson M; Langkilde AM; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Vaduganathan M; Solomon SD; McMurray JJV
JAMA Cardiol; 2023 Jun; 8(6):554-563. PubMed ID: 37099283
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
Kondo T; Wang X; Yang M; Jhund PS; Claggett BL; Vaduganathan M; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Langkilde AM; Petersson M; Zaozerska N; Bachus E; Solomon SD; McMurray JJV
J Am Coll Cardiol; 2023 Sep; 82(10):1014-1026. PubMed ID: 37610398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
